Adaptimmune Therapeutics (ADAP) Prices 20.5M ADS Offering at $11/ADS

Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 3,075,000 ADSs at the public offering price. The gross offering size for this offering is expected to be $225.5 million, excluding any exercise of the underwriters’ option to purchase additional ADSs. All ADSs in this offering are being sold by Adaptimmune with net proceeds to be used to advance the development of Adaptimmune’s immunotherapies into and through clinical trials as well as for other general corporate purposes. This offering is expected to close on or about June 4, 2020, subject to customary closing conditions.

Cowen and SVB Leerink are acting as joint book-running managers for the offering and Roth Capital Partners is acting as lead manager for the offering.

You May Also Be Interested In

• ESS Tech launches $3.2M stock offering at $0.50 per share
• Pyxis Oncology (PYXS) files for 39.2M share offering by selling stockholders
• Ensign Group expands credit facility to $800M, extends to 2031